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)*+,-./0,1(The objective of this selective EBM review is to determine whether or not
anti depressants are effective in the treatment of depressed patients who do not seek
psychotherapy.
STUDY DESIGN: Review of all English language primary randomized controlled trials
published from 2000-2009.
DATA SOURCES: Three randomized controlled trials were found using OVID, Medline,
EbscoHost, Pubmed, and Cochrane databases.
OUTCOMES MEASURED: The three trials measured the change in the severity of
depression symptoms using different outcomes: The Montgomery Asburg Depression
Scale, Hamilton Depression Rating Scale, and Hopkins Symptom Checklist Depression
Scale.
RESULTS: Hermens et al. found that the use of usual care and paroxetine is no more
effective than usual care at fifty-two weeks. Barrett et al. found that paroxetine is no
more effective than placebo in the treatment of depression at eleven weeks. Williams et
al. found that paroxetine is more effective than placebo in decreasing depressive
symptoms, in older adults, at eleven weeks.
CONCLUSIONS: The work of Hermens and Barrett demonstrated that paroxetine is no
more effective than usual care in the treatment of depression within the general
population. Williams RCT’s demonstrates that paroxetine may be effective in the
treatment of depression in older adults.
KEY WORDS: depression, anti depressants, treatment + depression
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Depression is a serious mental illness characterized by a depressed mood in
conjunction with fatigue, changes in sleep patterns, changes in eating patterns, irritability,
and the inability to enjoy things that one previously enjoyed. Because depression is a
spectrum disorder that ranges from dysthymia to major depression, the treatments are
numerous and diverse. It can include psychotherapy, medication, electroconvulsive
therapy, or any combination. The first line treatment for people with depression involves
antidepressant therapy, most commonly in the form of selective serotonin reuptake
inhibitors (SSRI’s), together with outpatient psychotherapy4. It is not currently known
whether antidepressant therapy is effective without concurrent psychotherapy. This paper
analyzes three randomized controlled studies to determine the effectiveness of
antidepressants when not in conjunction with psychotherapy.
Despite great progress in the treatment and diagnosis of depression, it still
continues to be incredibly common within the general population. The lifetime
prevalence of major depression is 7-12% and 20-25% in men and women respectively 2,
which in recent years has accounted for up to 9.7 million office visits5. Among patients
with health related comorbidities the prevalence is believed to be as high as 20-40%5.
The yearly cost of depression in the United States is projected to be as high as twenty six
billion dollars; with indirect costs as high as fifty billion dollars5.
Due to time constraints, managed care, and the stigma attached with
psychotherapy, physician assistants will find themselves with patients for whom
psychotherapy is not an option. Keeping in mind the prevalence, costs, morbidity, and
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mortality associated with depression, the need for determining the effectiveness of
antidepressants as a sole treatment becomes apparent.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not
antidepressants are effective in the treatment of depressed patients who do not seek
psychotherapy.
METHODS
In order for studies to be included for review, all patients had to be over the age of
18, in the outpatient setting and also have a clinical diagnosis of depression using the
Diagnostic and Statistic Manual of Mental Disorders (DSM). The intervention for all
studies was oral Paroxetine and the comparison group was no treatment other than usual
care or a placebo pill. The outcomes that were measured in each study attempted to
capture the change in depressive symptoms. The three studied included are Randomized
Controlled Trials (RCT’s).
Peer reviewed journals written in the English language were searched using
OVID, Medline, EbscoHost, Pubmed, and Cochrane databases between December 2010
and January of 2011. The key words used in searches were depression, antidepressants,
and treatment+ depression. The inclusion criteria for each study required that it be an
RCT with Patient Oriented Evidence that Matters (POEM) and have been completed in
the past 10 years. The exclusion criteria were studies with patients under 18, patients
currently on antidepressants, and those having previous issues with substance abuse. All
searches were conducted by the author and Stephanie Ferretti of the Philadelphia College
!
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of Osteopathic Medicine Library. All studies were published. The statistics reported
include p value, relative risk ratio (RRR), and numbers needed to treat (NNT).
A. Table 1 - Demographics & Characteristics of included studies
Study

Type #
patients

Age
(yrs)

Inclusion Criteria

W/D

Barrett,
2001 (1)

RCT

241

18-59

Paroxetine

Hermens,
2007 (3)

RCT

181

18+

3/9 DSM-III-R
20
symptoms for major
depression for at least 4
weeks, DSM-III-R
criteria for dysthymia or
minor depression, >10
on HDRS
3-6/9 DSM-IV symptoms 21
of depression, significant
distress/impairment,
symptoms daily for 2
weeks

Williams,
2000 (5)

RCT

415

60+

Minor
depression/dysthymia
diagnosed by DSM-IIIR,
HDRS >9, 3-4 symptoms
for at least 4 weeks

Paroxetine

65

Interventio
ns

Paroxetine

OUTCOMES MEASURED:
The study performed by Hermens et al. took place in the Netherlands with
patients recruited by primary care physicians. Upon identification of possible patients,
research assistants conducted baseline interviews in which the patient received an
explanation of the study and then informed consent was obtained. The patients were then
randomized into usual care plus antidepressants or usual care alone. At the conclusion of
the study the patient’s depressive symptoms, as measured by The Montgomery Asberg
Depression Rating Scale, were compared to their symptoms at intake.

!

McGuinness, Antidepressants as Monotherapy,!,!
!
The study performed by Barrett et al. took place in New Hampshire and
Washington with patients recruited by primary care physicians at these two sites. Patients
who met all criteria were consented and randomized to paroxetine, placebo, or ProblemSolving Treatment for Primary Care. At the conclusion of the study the patients’
depressive symptoms, as measured by the Hamilton Depression Rating Scale, were
compared to their symptoms at intake.
The study performed by Williams et al. took place at four geographically and
clinically diverse sites (location unspecified) with patients recruited through referral from
various primary care clinics. Patients who met all criteria were consented and randomized
to placebo, paroxetine, or Problem-Solving Treatment for Primary Care. At the
conclusion of the study the patients’ depressive symptoms were measured using the 20item Hopkins Symptom Checklist Depression Scale.
RESULTS:
The study by Hermens et al. from 2007 used patients over the age of 18 with a
diagnosis of minor or mild-major depression. The test group was given 20 mg/day of
oral paroxetine and usual care for three months. The control group received only usual
care for three months. Patients in the test group could increase their dose of paroxetine to
40mg a day, if at 4 weeks their clinical response was poor. The study was conducted for a
total of 52 weeks. Hermens et al. reported that greater than 25% of patients were not
treated according to protocol. Table 2 shows that there was a 14.7 point decrease in the
Montgomery Asberg Depression Rating Scale score from baseline at 52 weeks with usual
care and paroxetine. For patients with usual care only, there was a decrease of 12.6
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points. The CI at 95% is wide at -6.2;1.9 with a standard deviation of 24.2 The data
presented is continuous and cannot be converted to dichotomous data because the author
does not include individual scores for the patients, only the average of all test subjects.
This study fails to show that usual care and paroxetine are any more effective than usual
care at 52 weeks.
Table 3: The Effect of Antidepressants on Montgomery Asberg Depression Rating Scales
Hermens et al.
Outcomes
Usual Care +
measured
Paroxetine

Usual Care

Change in
-14.8
-12.7
MADRS*
from baseline
*Montgomery Asberg Depression Rating Scales

Mean difference
2.1

Confidence
interval at
95%
-6.2; 1.9

The study by Barrett et al. from 2001 used patients aged 18-59 with minor
depression or dysthymia. The test group received oral paroxetine that was started at
10mg/day and increased to 20mg/day at week 2. At week 4 or 6 the dose could be further
increased to 30mg per day and at week 6 or 8 to 40mg if there was limited clinical
improvement. The control group received a placebo that was titrated in the same fashion.
As is shown in table 4, 60.7% of those who received paroxetine and 65.6% of those who
received placebo, achieved remission as defined by a score of 6 or less on the Hamilton
Depression Rating Scale (p= .906). The relative benefit increase was found to be -0.0747,
absolute benefit increase -4.90, and number needed to treat= -20.0. This study fails to
show that paroxetine is any more effective than placebo in the treatment of depression at
11 weeks.
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Table 4: The Effect of Antidepressants on Rate of Remission as Defined by Hamilton
Depression Rating Scale
Barrett et al.
Outcomes
Paroxetine
measured
Remission
60.7
Rate (%)

Placebo

p

RBI

ABI

NNT

65.6

-0.906

-0.0747

-4.90

-20.0

The study by Williams et al. from 2000 used patients with a clinical diagnosis of
dysthymia and minor depression over the age of 60. Oral paroxetine was administered to
their test group which was started at 10mg/day and then subsequently increased to
20mg/day at week 2. At week 4 or 6 the dose could be further increased to 30mg per day
and at week 6 or 8 to 40mg if clinical improvement was limited. The control group
received placebo that was titrated in an identical fashion. As is shown in table 5, 53.1%
of those who received paroxetine and 49.1% of those who received placebo achieved
remission as defined by a score of 6 or less on the Hamilton Depression Rating Scale (p=
0.004). The relative benefit increase was found to be 0.0815, absolute benefit increase 4,
and number needed to treat= 25. This study shows that paroxetine is more effective than
placebo in the treatment of depression at 11 weeks.
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Table 5: The Effect of Antidepressants on Rate of Remission as Defined by the Hopkins
Symptom Checklist Depression Scale
Williams et al.
Outcomes
Paroxetine
measured
Remission
53.1
Rate (%)

Placebo

p

RBI

ABI

NNT

49.1

-0.906

-0.0815

4

25

In the study by Williams at al. 9.7% of patients taking paroxetine dropped out due
to adverse side effects whereas 5.7% of those taking placebo dropped out due to side
effects. NNH was calculated to be 27. This is the only study, of the three, to give data on
the patients who dropped out as a result of adverse side effects. None of the studies give
any indication as to the side effects or adverse reactions patients experienced.
Table 5: Harms Associated With Treatment
Study

RRI

ARI

NNH

.64

3.4

27

Barrett, 2001 (1)
Hermens, 2007 (3)
Williams, 2000 (5)

DISCUSSION:
There was a great degree of incongruence between the three studies included for
review. The most important being that the only study to show paroxetine as an effective
treatment only included patients over the age of sixty. This leaves questions as to whether
paroxetine is an effective treatment in this specific population. Other discrepancies
!
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between the studies include differences in the length of treatment as well as differences in
disease severity of participants.
Although the efficacy of selective serotonin reuptake inhibitors (SSRIs) as
treatment for depression is questionable, they have long been used as part of the
treatment in numerous other conditions including panic disorder, obsessive compulsive
disorder, social phobia, post traumatic stress disorder, and premenstrual dysmorphic
disorder. None of the included studies disclosed the cause of patient drop out as a result
of adverse side effects, but it is apparent that SSRIs are not without side effects. Current
black box labeling of SSRIs warn of an increased risk of suicide in patients with major
depressive disorders, during the first two months of treatment. In addition, patients taking
SSRIs are at risk for serotonin syndrome, which is a life threatening disorder
characterized by excess serotonin that manifests itself as restlessness, hallucinations, loss
of coordination, fast heart beat, rapid changes in blood pressure, increased body
temperature, overactive reflexes, nausea, vomiting, and diarrhea. Some of the more minor
and yet more common side effects include anxiety, constipation, insomnia, erectile
dysfunction, and decreased libido4.
CONCLUSION:
Using the three studies included for systematic review, it cannot be concluded that
antidepressants, as monotherapy, are an effective treatment for depression in the general
population. However, based on the results of the study by Williams et al, antidepressants
may be effective in adults over the age of 60 with a diagnosis of depression.
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Given the profound economic and social impact of depression, it would be
beneficial to further study the efficacy of antidepressants as monotherapy in specific
subpopulations including teens and middle-aged adults. It would also be advantageous to
closely study their effect on the specific clinical presentations of depression, namely
dysthymia, mild depression, and major depression. Lastly, it would be helpful to know
the effectiveness of antidepressants at distinct time intervals within a depressive episode.
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